Introduction
Hepatitis B virus (HBV) infection is one of the major public health problems in Egypt; its prevalence was (1.4%) with higher prevalence in urban than rural area [1] .
All patients with untreated chronic hepatitis B virus infection have a high risk of development of cirrhosis and hepatocellular carcinoma [2] .
The aim of treatment is decreasing HBV DNA levels, decreasing hepatic inflammation and improving laboratory parameters of disease activity [3] .
Entecavir is a potent oral guanosine nucleoside analogue for treatment of HBeAg-positive or negative chronic HBV infection; it's safe and effective in treatment of naive and lamivudine resistant patients [4] .
Chronic liver injury causes necrosis and apoptosis of parenchymal cells and replacement by extracellular matrix, with disease progression the liver parenchyma replaced by scar tissues with abnormal vascular architecture and finally organ dysfunction [5] .
Coagulation cascade is one of main factors in development of hepatic fibrosis, in which Thrombin is cause change of fibrinogen to fibrin which appear in the hepatic tissue during acute and chronic liver injury [6] .
Thrombotic risk factors play an important role in hepatic fibrosis in patients with chronic HBV or chronic HCV [7] .
Type IV collagen is a direct marker of hepatic fibrosis which indicate hepatic extracellular matrix transformation, and its concentration affected by degree of liver cell loss and disturbed hepatic function [8] .
Hepatic fibrosis is the main complication of chronic hepatic disease that eventually leads to cirrhosis with subsequent complications [9] . So, in this study we aimed to evaluate the role of pretreatment serum level of factor IV collagen as a predictor of post antiviral therapy virological response with hepatic fibrosis regression.
Aim of the Work
To evaluate the role of serum factor IV collagen level as a predictor of post antiviral therapy virological response with hepatic fibrosis regression.
Materials and Methods

Study Participants
This prospective cohort study has been conducted on 74 naieve patients with chronic HBV infection with variable degree of hepatic fibrosis (F2, F3, ≥F4), viral load (HBV DNA) from 16 up to >1,000,000 copies/ml, and variable degree of abnormality in laboratory parameters of liver functions. All patients attend out patient's clinic of Tropical Medicine and Gastroenterology Departments during the period from April 2017 till May 2018.
Exclusion criteria included: 1) co-infection with HCV, HDV, or HIV; 2) excessive alcohol consumption (>21 drinks per week in men and >14 drinks per week in women); 3) dynamic CT imaging of HCC or history of HCC. All patients treated with Entecavir 0.5 mg or 1 mg according to severity of hepatic condition, once daily oral on empty stomach for 1 year. Patients were treated according to EASL 2017 guidelines for HBV infection treatment [2] .
At base line and one year post antiviral treatment all included patients subjected to complete history taking , full clinical examination, liver function tests, liver fibrosis assessment (F2-≥ F4) using fibroscan, factor IV collagen measurement as a serum direct fibrosis markers, aspartate aminotransferase-to-platelet ratio index (APRI) score [10] and fibrosis index based on four factors (FIB-4) score [11] where increase in FIB-4 and APRI scores correlate with increase in hepatic fibrosis [12] [13], they calculated according to the following equation. 
Sampling
8 ml of venous blood were collected from each patients under aseptic precautions and divided in 4 tubes: 1) 2 tubes containing EDTA (sterile EDTA containing Vacutainer) one for platelet count used directly and the other for HBV-DNA centrifuged, separated in sterile tube and frozen at −20˚C till the time of the assay. 2) Plain glass tube for liver function tests, then after clotting, the tube was centrifuged at 3000 rpm for 5 min at room temperature and then the serum was separated to be used for estimation of liver function (including liver enzymes, albumin, bilirubin-total and direct) and type IV collagen. 3) Sodium citrate containing tube (Vacutainer) for prothrombin time, prothrombin concentration and INR.
The Laboratory Tests
1) The platelet count was done by Celtak haematology analyzer (Nihon Kohden, Japan).
2) The liver function tests (total and direct bilirubin, serum albumin, AST and ALT) were done by BT 1500 full automated chemistry analyzer (Bioticnica, Italy).
3) The prothrombin time, concentration and INR was done by done using Thromborel S kits (Siemens, Germany) using BE coagulator (Germany). 4) HBV-DNA was done by StepOnePlus™ Real-Time PCR System (ThermoFisher Scientific, USA) using Taqman PCR mastermix (ThermoFisher Scientific, USA) after DNA extraction by Qiagen kit (Qiagen, inc, USA) and according the manufacture's pamphlet. 5) Type IV collagen was assayed using quantitative sandwich ELISA technique with Human col IV ELISA kit (Mybiosource, inc, USA) and according the manufacture's pamphlet. 
Transient Elastography
Ethical Approval
The study protocol was approved by the ethical committee of our institution and all our patients provided informed consent before inclusion in the study The laboratory measures among chronic HBV infected patients including factor IV collagen, mean platelet count, and liver function tests together with mean FIB score and APRI score before and one year of regular therapy are presented in Table 2 , with significant improvement of them except INR which show non-significant post treatment improvement (p < 0.111).
All included patients achieve Virological response with undetectable HBV DNA PCR (<16 IU/ml) during regular treatment with Entecavir 0.5 mg/d or 1mg/day for one year (100%).
There were also significant end treatment improvements in mean FIB score and APRI score 1.56 ± 1.02 (p < 0.0001***) and 0.50 ± 0.28 (p < 0.0001***) respectively ( Table 2 ).
In our study 49 (66.22%) of included patients showed post treatment reduction in their level of hepatic fibrosis (Responder) opposite to 25 (33.78%) had no post treatment improvement in degree of hepatic fibrosis (Non-responder).
Pretreatment and Post Treatment Improvement in Degree of Liver Fibrosis in Responder Patients
As regard hepatic fibroscan of the responder group: With significant p value (<0.0001***). This is illustrated in Table 3 . non-responder patients, the responder group had mild pretreatment impairment in their laboratory parameters. This is illustrated in Table 4 . Figure 1 . ROC curve of pretreatment laboratory parameters in responderpatients, that show statistically significant difference compared to non-responder group.
Pretreatment Laboratory
Laboratory Parameters in Responder Patients
Discussion
Progression of hepatic fibrosis is associated with increased risk of liver decompensation, and development of hepatocellular carcinoma (HCC) [16] .
Chronic hepatitis B virus treatment with nucleotide analogs (NUCs) leads to clinical improvement and reduces risk of HCC development [17] .
Entecavir is potent new NAs generation with low risk of resistance, however
NAs don't have immunomodulatory effects so, prolonged treatment is usually required to prevent viral relapse [18] .
In this prospective study we try to assess degree of improvement in hepatic fi- We have significant post treatment improvement in the level of hepatic fibrosis in 66.22% of our patients which assessed by evaluated by the decrease parameters of hepaticfibroscan.
This was in accordance with Chon et al. [19] who found significant decreased in level of hepatic fibrosis over 5 years of nucleat(s) ide therapy with the best fibrosis level reduction in the first year.
Also Kose et al. [20] and Xu et al. [21] found that entecavir is an effective treatment for patients with chronic hepatitis B, with both histological improvement and virological suppression.
Both APRI and FIB-4 scores are suitable non-invasive markers for detecting marked hepatic fibrosis and liver cirrhosis in patients with chronic hepatitis B virus infection [22] .
In our study we have significant improvement in both FIB-4 and APRI scores after one year or regular antiviral treatment compared to baselines values (P < 0.0001***).
With our study, Koksal et al. [23] found marked decrease in both APRI and FIB-4 scores one year post entecavir antiviral therapy and both of them could be used for monitoring treatment response.
In contrary, Chon et al. [19] found that no annual significant improvement in both FIB-4 and APRI scores with regular antiviral therapy, however, significant post treatment improvement in both FIB-4 and APRI scores were detected after 5 years of regular antiviral treatment.
On the other hand Kim et al. [24] reported that post entecavir antiviral therapy reduction in APRI or FIB-4 scores didn't correlate with reduction of hepatic fibrosis estimated by liver biopsy.
In our study we have significant post treatment increase in platelet count.
This come in agreement with Wang et al. [25] , who found significant increase in Platelets count after entecavir therapy and it was correlated with improvement of hepatic fibrosis. In our study, we have significant improvement of bilirubin, albumin and liver enzymes after one year of regular antiviral therapy.
This come in agreement with Chang et al. [26] who conclude that naive chronic hepatitis B virus infected patients even those with advanced hepatic fibrosis achieve normalization of ALT after entecavir antiviral therapy.
Also Kim et al. [24] found significant decrease in mean values of ALT, AST, and bilirubin with significant increase in mean albumin level after entecavir antiviral therapy.
In contrary, Wong et al. [27] reported that entecavir treatment in patients with acute exacerbation of chronic hepatitis B (which considered in their study as ALT above 10 time normal level and bilirubin above 3 times normal value) is associated with early mortality with jaundice, ascites and hepatic encephalopathy. In our patients pretreatment ALT and bilirubin don't exceed 4 times and 3 times upper limit of normal respectively.
DOI
The results of the current study as regard the therapeutic efficacy of entecavir as oral antiviral therapy revealed 100% virological response with undetectable HBV DNA after one year of regular therapy.
In agreement with this findings, Myung et al. [28] , who reported that entecavir therapy had excellent efficacy in naive chronic hepatitis B virus infected patients. Also our findings were in line with Akbar and Fallatah [29] , who reported that entecavir was effective for the treatment of naive and experienced chronic hepatitis B virus infected patients.
On the opposite side, Chon et al. [30] reported that some naive chronic hepatis B virus infected patients develop partial virological response which defined according to EASL guideline 2 as a decrease in HBV DNA of more than 1 log 10 IU/ml but detectable HBV DNA > 35 IU/ml after at least 12 months of therapy. Factor IV collagen is non-invasive serological marker to identify significant fibrosis in patients with chronic hepatitis B [31] .
In our study we have significant decrease in factor IV collagen one year post entecavir antiviral therapy (p < 0.012). This come in agreement with Liang and Li [32] , who found significant decrease of factor IV collagen in patients treated with entecavir antiviral therapy (p < 0.05).
Our study reveals that pretreatment low level of serum bilirubin, mild impairment of serum INR, mild degree of liver stiffness as detected by fibroscan and low level of serum factor IV collagen are associated with post treatment improvement in the level of hepatic fibrosis in naive chronic hepatitis B virus infected patients.
In conclusion, in chronic HBV infected patients, low pretreatment serum level of factor IV collagen are good predictor of post treatment virological response and hepatic fibrosis regression.
Study Limitations
Lack of a long-term follow-up period after the treatment completion is the major limit of this study especially for non-responder patients.
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